Eluvia Drug-Eluting Stent

GPTKB entity

Statements (48)
Predicate Object
gptkbp:instance_of gptkb:medical_devices
gptkbp:approves gptkb:FDA
gptkbp:clinical_trial conducted for efficacy
gptkbp:coat_of_arms gptkb:sirolimus
gptkbp:delivers sirolimus over time
gptkbp:designed_for treatment of peripheral artery disease
gptkbp:developed_by gptkb:Boston_Scientific
gptkbp:diameter various diameters
gptkbp:features drug-eluting technology
gptkbp:has_clinical_benefits long-term outcomes
gptkbp:has_length_options various lengths
https://www.w3.org/2000/01/rdf-schema#label Eluvia Drug-Eluting Stent
gptkbp:indication femoral-popliteal artery lesions
gptkbp:is_associated_with lower complication rates
gptkbp:is_available_in multiple countries
gptkbp:is_available_on gptkb:2018
gptkbp:is_compared_to bare-metal stents
gptkbp:is_compatible_with angioplasty procedures
gptkbp:is_considered a standard of care
a breakthrough technology
gptkbp:is_evaluated_by randomized controlled trials
long-term safety
safety and effectiveness
other drug-eluting stents
gptkbp:is_informed_by patient outcomes
gptkbp:is_inserted_via catheterization
gptkbp:is_part_of gptkb:guidelines
interventional cardiology
vascular intervention strategies
Boston Scientific product line
gptkbp:is_promoted_by improving blood flow
gptkbp:is_protected_by restenosis
gptkbp:is_recognized_by medical associations
gptkbp:is_recommended_by vascular specialists
gptkbp:is_subject_to post-market surveillance
gptkbp:is_supported_by clinical evidence
gptkbp:is_tested_for clinical studies
gptkbp:is_used_by interventional radiologists
gptkbp:is_used_for stenosis
gptkbp:is_used_in clinical practice
peripheral vascular interventions
gptkbp:made_of biocompatible materials
gptkbp:marketed_as a minimally invasive solution
gptkbp:provides improved patency rates
gptkbp:reduces restenosis rates
gptkbp:used_in endovascular procedures
gptkbp:bfsParent gptkb:Boston_Scientific
gptkbp:bfsLayer 4